All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld MedTech Perspectives » Growing pains: TAVR still in adolescence?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Growing pains: TAVR still in adolescence?

Oct. 29, 2013
By Mark McCarty
No Comments

Anatomy; not the only thing about aortic valves that's complicated
Anatomy; not the only thing about aortic valves that's complicated

It's tough to know what's "normal" for the natural history of a medical device, but it appears the path to maturity for those first-of-a-kind, high-risk circulatory system devices is more drawn out than in times gone by. Now that TCT 2013 is upon us, we might reflect on a third anniversary of sorts of the Sapien valve, a member of a class of devices that may or may not be described as a mature technology.

The fanfare over the Sapien TAVR at TCT 2010 might seem a bit conspicuous now after the passage of 37 months. Edwards Lifesciences had unveiled data from the Partner trial that year, and the consensus seemed to be that the trial was a resounding success. Still, another year would pass before FDA approved the device, a stark reminder of the device lag American patients have faced for a number of years now.

Edwards purportedly invoked parallel FDA/CMS review, but it did not appear CMS got involved until Edwards had wrapped up its first regulatory filing, leading one to wonder about the meaning of “parallel.” CMS had proposed covering the device under coverage with evidence development with a mandate for post-approval studies intended to demonstrate superiority to the comparator, but doctors were quick to lambaste the superiority idea publicly, even if Edwards was mum in public on the notion.

Everyone still remembers the patent battles that have plagued coronary artery stents, so of course Edwards and Medtronic are embroiled in their own patent showdown over TAVR. The Supreme Court recently opted not to hear the case, but a lower court will still review the argument for injunction of the firm's CoreValve. Medtronic is not out of the woods just yet, and hence Edwards could have the U.S. market to itself for several more years.

Docs annoyed over both coverage and reimbursement

Another consideration in all this is that while CMS agreed in May 2012 to cover TAVR under CED, there has been a ton of grumbling over Medicare reimbursement for the device/procedure. Among their grievances is that payment is scattered across several diagnostic-related groups, and the payment level depends in part on whether the hospital provides indirect medical education. Of course, the Centers for Medicare & Medicaid Services made it clear early on it didn't want every Dr. Tom, Dick and Harry practicing the device as evidenced by the institutional experience and staffing mandates that are conditions of coverage. So we might safely assume these nagging reimbursement issues won't ease anytime soon.

One of the really interesting features of TCT 2013 is that the discussions of adverse events are picking up, including thrombosis. Don’t get me wrong, they’re not piling on the way electrophysiologists did on the St. Jude Riata. Still, docs are clearly not keen on repeating the roller-coaster ride provided by drug-eluting stents. If memory serves, the rates of thrombosis between DES and bare-metal stents evened out after two or three years, but there was a lot of whiplash for device makers, docs and FDA. None of them is in a hurry to revisit that experience, especially FDA, one of whose members characterized the episode as the “DES trauma.”

To summarize: We have the world's best market for devices served by a single manufacturer; a patent fight between that firm and the only competitor in a position to challenge anytime soon; coverage that requires financing a registry; reimbursement that leaves most interventional cardiologists with the blues; and a cadre of researchers intent on shining a light on every little blemish. Excuse me for invoking a cheap simile, but that sounds less like a device that's ready for prime time and more like a technology that still has a zit or two to clear up.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing